Evidence map›Paper›PMID 19616028›Full record

ReviewAntiviral research2010

Understanding the alphaviruses: recent research on important emerging pathogens and progress towards their control.

E A Gould, B Coutard, H Malet, B Morin, S Jamal, S Weaver, A Gorbalenya, G Moureau, C Baronti, I Delogu and 5 more

Abstract readReview
In one paragraph

Review in Antiviral research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 114 citations in OpenAlex.

  1. Article
  2. Journal of medicinal chemistry · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Emerging arboviruses: Why today?One health (Amsterdam, Netherlands) · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 4 countries.

E A GouldInstitut de Recherche pour le Développement UMR190/Unité des Virus Emergents, Université de la Méditerranée, Marseille, France. eag@ceh.ac.uk
B Coutard
H Malet
B Morin
S Jamal
S Weaver
A Gorbalenya
G Moureau
C Baronti
I Delogu
N Forrester
M Khasnatinov
T Gritsun
X de Lamballerie
B Canard
Institut de Recherche pour le Développement · FRArchitecture et Fonction des Macromolécules Biologiques · FRCentre National de la Recherche Scientifique · FRThe University of Texas Medical Branch at Galveston · USInstitut de Neurobiologie de la Méditerranée · FRLeiden University Medical Center · NLUniversity of Reading · GB

Funding

WRCE Nonhuman Primate CoreU54AI057156 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WALKER, DAVID H · 2003 to 2013
$102.6M
Mechanisms of sylvatic dengue emergenceR01AI069145 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2008 to 2011
$2.5M
VEE Virus Infection on the Mosquito VectorR01AI071192 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2008 to 2013
$2.0M
Medical Research Council G0801208NIAID NIH HHS R01 AI069145NIAID NIH HHS R01-AI069145NIAID NIH HHS R01 AI071192NIAID NIH HHS R01-AI071192NIAID NIH HHS U54 AI057156NIAID NIH HHS U54-AI057156
6 · The paper itself

Abstract

The alphaviruses were amongst the first arboviruses to be isolated, characterized and assigned a taxonomic status. They are globally very widespread, infecting a large variety of terrestrial animals, insects and even fish, and circulate both in the sylvatic and urban/peri-urban environment, causing considerable human morbidity and mortality. Nevertheless, despite their obvious importance as pathogens, there are currently no effective antiviral drugs with which to treat humans or animals infected by any of these viruses. The EU-supported project-VIZIER (Comparative Structural Genomics of Viral Enzymes Involved in Replication, FP6 PROJECT: 2004-511960) was instigated with an ultimate view of contributing to the development of antiviral therapies for RNA viruses, including the alphaviruses [Coutard, B., Gorbalenya, A.E., Snijder, E.J., Leontovich, A.M., Poupon, A., De Lamballerie, X., Charrel, R., Gould, E.A., Gunther, S., Norder, H., Klempa, B., Bourhy, H., Rohayemj, J., L'hermite, E., Nordlund, P., Stuart, D.I., Owens, R.J., Grimes, J.M., Tuckerm, P.A., Bolognesi, M., Mattevi, A., Coll, M., Jones, T.A., Aqvist, J., Unger, T., Hilgenfeld, R., Bricogne, G., Neyts, J., La Colla, P., Puerstinger, G., Gonzalez, J.P., Leroy, E., Cambillau, C., Romette, J.L., Canard, B., 2008. The VIZIER project: preparedness against pathogenic RNA viruses. Antiviral Res. 78, 37-46]. This review highlights some of the major features of alphaviruses that have been investigated during recent years. After describing their classification, epidemiology and evolutionary history and the expanding geographic distribution of Chikungunya virus, we review progress in understanding the structure and function of alphavirus replicative enzymes achieved under the VIZIER programme and the development of new disease control strategies.

Indexed as

AlphavirusAlphavirus InfectionsAnimalsBiomedical ResearchChikungunya virusCommunicable Diseases, EmergingEnzymesEuropean UnionHumansViral ProteinsEnzymesViral Proteins

Identifiers

PMID19616028
PMCPMC7114216
OpenAlexW2073517039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.